Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
Open Access
- 20 February 2013
- journal article
- research article
- Published by Springer Nature in BMC Nephrology
- Vol. 14 (1) , 44
Abstract
Some hemodialysis patients require large doses of erythropoiesis-stimulating agents (ESAs) to manage anemia. These patients, termed “ESA hyporesponsive,” have been characterized using various definitions. We applied three definitions of hyporesponsiveness to a large, national cohort of hemodialysis patients to assess the impact of definition on counts and on characteristics associated with hyporesponsiveness.Keywords
This publication has 13 references indexed in Scilit:
- Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2009
- Erythropoiesis‐stimulating agent hyporesponsiveness (Review Article)Nephrology, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- Effect of Intravenous Ascorbic Acid in Hemodialysis Patients With EPO-Hyporesponsive Anemia and HyperferritinemiaAmerican Journal of Kidney Diseases, 2006
- UNRESOLVED ISSUES IN DIALYSIS: Managing Erythropoietin HyporesponsivenessSeminars in Dialysis, 2006
- ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance.2006
- Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patientsNephrology Dialysis Transplantation, 2005
- Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patientsAmerican Journal of Kidney Diseases, 2003
- Identifying Persons with Diabetes Using Medicare Claims DataAmerican Journal of Medical Quality, 1999